NCT01782131View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

PHASE3CompletedINTERVENTIONAL
Enrollment

585

Participants

Timeline

Start Date

September 25, 2013

Primary Completion Date

July 10, 2019

Study Completion Date

September 10, 2019

Conditions
Fungal InfectionsInvasive Pulmonary Aspergillosis
Interventions
DRUG

Posaconazole

POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD

DRUG

Voriconazole

VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID

DRUG

Placebo

Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01782131 - A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) | Biotech Hunter | Biotech Hunter